Healthcare industry, invariably offers plethora of opportunities to investors. There are many ASX Healthcare Companies, which besides being well established are coming out with treatments for unmet medical needs. Some of the Best Healthcare Stocks, after initial breakthrough are getting ready to penetrate into large addressable health care market for their respective fields.
Mesoblast Limited (ASX: MSB)
Mesoblast Limited (ASX: MSB) announced its FY24 annual results for the period ended 30 June 2024, reporting a cash balance of $63.3 million USD (or $95.0 million AUD), with an additional $10.0 million USD set to become available if the FDA approves RYONCIL.
Net cash usage for operating activities decreased by 23% to US$48.5 million in FY2024 from US$63.3 million in FY2023, and Q4 FY2024 usage was down 37% to US$10.2 million compared to US$16.3 million in Q4 FY2023, primarily due to reduced manufacturing costs and payroll.
As of June 30, 2024, Mesoblast Limited reported total assets of $669.2 million, with current assets increasing to $86.5 million, primarily driven by $63.0 million in cash and cash equivalents.
MSB’s platform technology leverages mesenchymal precursor/stromal cells that are activated by multiple inflammatory cytokines through surface receptors, triggering a coordinated anti-inflammatory response. This shared mechanism of action underpins the efficacy of its products across various inflammatory conditions.
Looking ahead, Mesoblast is positioned for pivotal developments in FY2025. The resubmitted BLA for RYONCIL, targeting acute graft versus host disease in children, is under active FDA review with a decision anticipated by January 7, 2025.
The company is also preparing for a targeted commercial launch strategy, focusing on high-volume centers. For RYONCIL in adults, Mesoblast plans a label extension following pediatric approval, collaborating with BMT CTN for a pivotal trial. The Phase 3 trial for rexlemestrocel-L in chronic low back pain is underway, with RMAT designation enhancing its development prospects. REVASCOR received Rare Pediatric Disease and Orphan-Drug Designations for hypoplastic left heart syndrome, showing promising results in trials. Additionally, REVASCOR demonstrated efficacy in reducing major adverse cardiac events in heart failure patients with reduced ejection fraction and has received support for an accelerated approval pathway from the FDA.
Mesoblast presents a compelling investment opportunity, underpinned by its innovative approach to mesenchymal stem cell therapies and its strong position in the rapidly growing regenerative medicine market. The resubmitted BLA for remestemcel-L is a critical milestone, potentially unlocking substantial value upon approval. Additionally, Mesoblast's strategic partnerships and licensing agreements enhance its market reach and provide a layer of financial stability, which is particularly valuable in the volatile biotech sector.
With a robust pipeline and potential for significant growth following regulatory approvals, the stock could see substantial appreciation. A key focus is the development of rexlemestrocel-L (Revascor®) to address the treatment gap in chronic heart failure (CHF), a condition with high unmet need.
Immutep Limited (ASX: IMM)
On 14 August 2024, IMM reported that the first patient had been successfully dosed in the first-inhuman Phase I trial of IMP761.
Immutep Limited had earlier reported positive results from its final discussions with the FDA regarding the planned TACTI-004 Phase III trial of eftilagimod alfa (“efti”) in combination with KEYTRUDA® (pembrolizumab), MSD’s anti-PD-1 therapy, and histology-based platinum doublet chemotherapy for the treatment of first-line metastatic non-small cell lung cancer (1L NSCLC), regardless of PD-L1 expression. This lays a strong foundation for the development of an effective treatment for non-squamous and squamous 1L NSCLC patients who have high, low, or no PD-L1 expression and are eligible for anti-PD-1 therapy.
On 17 July 2024, IMM received regulatory clearance to initiate the first-in-human Phase I study of IMP761. The study is expected to enroll first participant during Q3 CY2024.
As of June 30, 2024, Immutep reported a robust cash and cash equivalent balance of approximately A$161.8 million, supplemented by a A$20 million bank term deposit, bringing the total cash position to A$181.8 million.
This financial strength provides an expected cash runway into late 2026. Overall, Immutep is well-positioned to advance its clinical trials and enhance shareholder value.
There is a significant multi-billion-dollar market opportunity for Efti similar to that currently enjoyed by KEYTRUDA in metastatic non-small cell lung cancer (NSCLC). The NSCLC drug market is estimated at US$ 24 billion, positioning Efti to potentially capture a substantial share of this highly profitable market. Additionally, in head and neck squamous cell carcinoma (HNSCC), where the drug market is valued at US$ 3 billion, Efti's FDA Fast Track designation accelerates its path toward approval, signaling the potential for rapid market entry.
Efti's prospective FDA approval and subsequent market penetration could actually bring revolution in treatment options, offering innovative therapeutic avenues and potentially transforming treatment standards for NSCLC patients.
Source: Company’s Report
Veye Pty Ltd(ABN 58 623 120 865), holds (AFSL No. 523157 ). All information provided by Veye Pty Ltd through its website, reports, and newsletters is general financial product advice only and should not be considered a personal recommendation to buy or sell any asset or security. Before acting on the advice, you should consider whether it’s appropriate to you, in light of your objectives, financial situation, or needs. You should look at the Product Disclosure Statement or other offer document associated with the security or product before making a decision on acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Any recommendation contained herein may not be suitable for all investors as it does not take into account your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure accuracy of the content and that the information is gathered and processed from reliable resources, we strongly recommend that you seek professional advice from your financial advisor or stockbroker before making any investment decision based on any of our recommendations. All the information we share represents our views on the date of publishing as stocks are subject to real time changes and therefore may change without notice. Please remember that investments can go up and down and past performance is not necessarily indicative of future returns. We request our readers not to interpret our reports as direct recommendations. To the extent permitted by law, Veye Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss, or data corruption) (as mentioned on the website www.veye.com.au), and confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report. Veye Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services.